Clinical trials · Minnesota
Systemic Sclerosis clinical trials in Minnesota
We’re tracking 8 recruiting systemic sclerosis studies with a site in Minnesota — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Minnesota
- NCT07497087RecruitingPhase 3
Study of nerandomilast for people with systemic sclerosis
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
Minneapolis, MinnesotaAges 18 years+ - NCT06328777RecruitingPhase 1/Phase 2
CABA-201 CAR T Cells For Systemic Sclerosis
This trial tests a new treatment called CABA-201, a type of CAR T cell therapy that targets a protein called CD19 on immune cells. It aims to calm the overactive immune system in people with Systemic Sclerosis and may help stop or slow damage to skin, lungs, and other organs.
Rochester, MinnesotaAges 18–75 - NCT07335562RecruitingPhase 3
Comparing a new cell therapy (zola-cel) to standard care for active systemic sclerosis
This study tests a new type of cell therapy (CAR T-cells) to see if it works better than current treatments for active systemic sclerosis. It is designed for people whose lung disease is not well controlled by standard therapy.
Rochester, MinnesotaAges 16 years+ - NCT06308978RecruitingPhase 1
Study of FT819 for B-cell autoimmune diseases
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
Minneapolis, MinnesotaAges 12–70 - NCT05869955RecruitingPhase 1
CAR T cell therapy for severe autoimmune diseases
This early-phase study tests an experimental immune-cell treatment that targets a protein called CD-19 to calm severe, treatment-resistant autoimmune disease. It may help people whose lupus, inflammatory muscle disease, skin/scarring lung disease, or rheumatoid arthritis are not controlled by standard medicines.
Rochester, MinnesotaAges 18 years+ - NCT06655896RecruitingPhase 2
Rapcabtagene Autoleucel for severe diffuse scleroderma
This trial tests an investigational cell therapy called rapcabtagene autoleucel for people with severe diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The treatment uses your own modified immune cells to potentially calm the disease activity.
Minneapolis, MinnesotaAges 18–70 - NCT06733935RecruitingPhase 1/Phase 2
Study of NKX019 for immune diseases
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
Minneapolis, MinnesotaAges 18–75 - NCT06796504Recruiting
Device study to help repair nerve coating in RRMS
This pilot study tests a device (the SetPoint System) that may help repair the protective coating around nerves in people with relapsing-remitting MS. It focuses on participants with a specific vision test delay and stable disease activity, and aims to see if the treatment can promote remyelination.
Plymouth, MinnesotaAges 22–50
Where these studies are running in Minnesota
Institutions with a site for the recruiting systemic sclerosis studies listed above.
- University of Minnesota · 3 studies
- Local Institution - 0022
- Local Institution - 0037
- Mayo Clinic
- Minnesota Center for Multiple Sclerosis
- Nkarta Investigational Site
What taking part in a systemic sclerosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Systemic Sclerosis trials in other states
Common questions
- Are there systemic sclerosis clinical trials in Minnesota?
- Yes. We're currently tracking 8 recruiting systemic sclerosis studies with a site in Minnesota, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a systemic sclerosis study in Minnesota?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Minnesota to take part?
- Not necessarily. These studies have a site in Minnesota, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a systemic sclerosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New systemic sclerosis studies open in Minnesota regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.